Categories AlphaGraphs, Earnings, Health Care
BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of 2023.
Total revenue declined 5% year-over-year to $2.46 billion. For the full year of 2023, the company expects revenues to decline in the mid-single digit percentage and projects adjusted earnings per share in the range of $15.00 to 16.00.
Net income attributable to Biogen Inc. was $591.6 million or $4.07 per share in Q2, compared to $1.06 billion or $7.24 per share last year. Adjusted earnings declined 23% to $4.02 per share.
Prior Performance
Most Popular
Citigroup set to report Q4 2025 earnings. Here’s what to expect
Citigroup Inc. (NYSE: C) has undergone a sweeping transformation in recent years, emerging as a more streamlined and profitable financial institution. The bank's performance in recent quarters has underscored the
Home Depot (HD), Lowe’s (LOW): Home improvement pressures not expected to abate soon
Home improvement retailers Home Depot (NYSE: HD) and Lowe’s Companies, Inc. (NYSE: LOW) have been facing a challenging operating environment for a while now. The companies have been battling macroeconomic
Earnings Summary: AngioDynamics (ANGO) Q2 FY26 sales increase 8.8%
Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026. In Q2, net sales increased 8.8% year-over-year to
